Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Oct 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to personalize the medication doses for children who have received a kidney transplant. The focus is on two specific medications, tacrolimus and mycophenolic acid, which help prevent the body from rejecting the new kidney. Researchers at Radboudumc will use a special tool called the InsightRX platform to analyze the levels of these medications in the blood. By measuring how much of the drug is in the body at different times, the pharmacist can recommend the best dose for each patient. The goal is to ensure that each child receives the right amount of medication to keep them healthy.

To be eligible for this study, participants must be between 0 and 18 years old and currently taking tacrolimus and/or mycophenolic acid after a kidney transplant. It's important that they have a reason for the dose measurement as decided by their doctor. Children who are unable to understand the study or cannot give consent, as well as those who do not speak Dutch, cannot participate. This trial is not yet recruiting participants, but it aims to improve future treatment by making sure the right dosage is given based on individual needs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Kidney transplant patients using tacrolimus and/or mycophenolic acid
• • Age between 0 and 18 years
• • Indication for an AUC measurement - judgement of clinician
• Exclusion Criteria:
• • Incapacitated patients
• • No informed consent
• • Not proficient in the Dutch language